EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Impact of Sodium‐Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With or Without Metabolic Syndrome

Yang Xu, Zixu Zhao, Hui Xu, Chao Jiang, Xiao Wang, Zejun Yang, Wenyu Shao, Hang Guo, Liu He, Qi Guo, Caihua Sang, Deyong Long iD und 3 weitere

Journal of Cardiovascular Electrophysiology · 2025-11 · 36 (11) · 2910-2918

DOI: 10.1111/jce.70073 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cardiovascular Electrophysiology, online erschienen am 03.09.2025. Verfasst von Yang Xu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Beijing Anzhen Hospital, National Clinical Research Center for Cardiovascular Diseases, Capital Medical University, Beijing…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Sodium-Glucose Transporter 2 Inhibitors, Metabolic Syndrome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: This study was supported by the Beijing Physician Scientist Training Project (BJPSTP-2024-21), Beijing Nova Program (20240484714, 20250484963), Beijing Natural….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The impact of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) on atrial fibrillation (AF) recurrence after catheter ablation is still inconclusive. Besides, their efficacy on AF recurrence stratified by metabolic syndrome (MetS) status remains unknown.

Methods

Patients with AF undergoing initial catheter ablation between January 2017 and December 2023 from the China‐AF Registry were included. Patients were 1:1 propensity score‐matched by SGLT2i use at discharge and stratified by baseline MetS status. The main outcome was the AF recurrence after a 3‐month blanking period.

Results

After propensity score matching, 573 patients in the SGLT2i group and 573 in the non‐SGLT2i group were included in the study. During the 20.5 ± 13.7 months follow‐ups, AF recurrence occurred in 100 patients (17.5%) in the SGLT2i group and 168 patients (29.3%) in the non‐SGLT2i group. SGLT2i was associated with lower AF recurrence (17.5% vs. 29.3%; HR 0.59, 95% CI: 0.46–0.75, p < 0.001), with consistent benefits in MetS (HR 0.61, 95% CI: 0.39–0.75, p = 0.03) and non‐MetS subgroups (HR 0.58, 95% CI: 0.43–0.78, p < 0.001, P interaction = 0.841). The effect of SGLT2i on the AF recurrence also remained consistent across the body mass index (BMI) spectrum ( P interaction = 0.740).

Conclusion

SGLT2i was associated with a lower risk of AF recurrence after catheter ablation independently of MetS status or BMI spectrum.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationSodium-Glucose Transporter 2 InhibitorsMetabolic SyndromeHumansMaleFemaleRecurrenceMiddle AgedTreatment OutcomeAgedRegistriesTime FactorsRisk FactorsRisk AssessmentChinaRetrospective StudiesHeart Rate

Stichwörter der Autor:innen

atrial fibrillationbody mass indexcatheter ablationmetabolic syndromesodium‐glucose cotransporter‐2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Beijing Anzhen Hospital, National Clinical Research Center for Cardiovascular Diseases, Capital Medical University, Beijing, China.
  • Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Heart Health Research Center, Beijing, China.

ORCID-Profile: Deyong Long, Jianzeng Dong

Förderung

  • This study was supported by the Beijing Physician Scientist Training Project (BJPSTP-2024-21), Beijing Nova Program (20240484714, 20250484963), Beijing Natural…

Zitieren

APA

Xu, Y., Zhao, Z., Xu, H., Jiang, C., Wang, X., Yang, Z., Shao, W., Guo, H., He, L., Guo, Q., Sang, C., Long, D., Du, X., Dong, J., & Ma, C. (2025). Impact of Sodium‐Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With or Without Metabolic Syndrome. Journal of Cardiovascular Electrophysiology, 36(11), 2910-2918. https://doi.org/10.1111/jce.70073

Vancouver

Xu Y, Zhao Z, Xu H, Jiang C, Wang X, Yang Z, et al. Impact of Sodium‐Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With or Without Metabolic Syndrome. Journal of Cardiovascular Electrophysiology. 2025;36(11):2910-2918. doi:10.1111/jce.70073

BibTeX
@article{Xu2025,
  author = {Xu, Yang and Zhao, Zixu and Xu, Hui and Jiang, Chao and Wang, Xiao and Yang, Zejun and Shao, Wenyu and Guo, Hang and He, Liu and Guo, Qi and Sang, Caihua and Long, Deyong and Du, Xin and Dong, Jianzeng and Ma, Changsheng},
  title = {Impact of Sodium‐Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With or Without Metabolic Syndrome},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2025},
  volume = {36},
  number = {11},
  pages = {2910--2918},
  doi = {10.1111/jce.70073}
}
Kostenlos starten →